Skip to main content

Search form

Search

Medicines for Malaria Venture

Developing antimalarials to save lives

Research & Development
Access
Partnering
Our impact
About us
Malaria & medicines
Newsroom
MMV Open

Home
Newsroom
News & Press Releases

News & Press Releases

Filter

Category

Topic

Search Terms

404 found

Malaria continues to strike pregnant women and children hardest and new tools are critical, according to WHO’s latest report

Laboratory image

Research for new drugs against neglected diseases and malaria in Brazil to receive funding boost totaling BRL 43.5 million

MMV presents Lifetime Achievement Awards to three longstanding collaborators

Country leaders pledge to boost malaria innovation and access to new and existing antimalarials

Brazil becomes first malaria-endemic country to approve single-dose tafenoquine (Kozenis) for radical cure of P. vivax malaria

Access & product management

MMV and PATH strengthen ties with APLMA in the fight against relapsing malaria

WHO issues information note about Pyramax® (artesunate-pyronaridine) for uncomplicated malaria

MMV contributes to the fight against schistosomiasis

Via Grand Challenges Africa, MMV supports eight African drug discovery scientists

Two reports on malaria eradication underline need for new tools and interventions

MMV awards its Project of the Year 2018 to University of Dundee researchers

MMV launches new P. vivax malaria information hub

Access & product management

Life-saving malaria project in Zambia to expand

MMV participates in Swiss World Malaria Day event

Prof Jonathan Vennerstrom receives prestigious ACS Award for Creative Invention

PATH and MMV launch 5-year global initiative to support elimination of relapsing malaria

Access & product management

Photo: Anna Wang/MMV

Europe-Africa partnership spearheads development of next-generation antimalarial drug

MMV and DNDi make 400 compounds available to stimulate research into new drugs for pandemic diseases

R&D, Open source

Two positive phase III studies of tafenoquine for the radical cure of Plasmodium vivax malaria published in The New England Journal of Medicine

Professor Michael Ferguson receives Knighthood in New Year’s Honours List

2018 - A triumph of partnerships

Open source effort identifies hundreds of compounds that could protect vulnerable populations from malaria

Access to Medicines Index highlights role of collaboration in stimulating R&D

R&D, Access & product management

Fosun Pharma’s medicine to protect pregnant women from malaria first to be approved by WHO

Partner, Access & product management

World Malaria Report highlights importance of country-led efforts to defeat malaria in highest burden countries

Professor James McCarthy elected Fellow of Australian Academy of Health and Medical Sciences

Ray Chambers appointed WHO Ambassador for Global Strategy

Single-dose tafenoquine for radical cure of P. vivax malaria submitted for regulatory approval in Brazil

Access & product management

Kozenis (tafenoquine) approved by the Australian Therapeutic Goods Administration for the radical cure of P. vivax malaria

Access & product management

Severe malaria case fatality reduced by 96% in pilot project in Zambia led by Transaid, MMV and partners

Access & product management

US FDA approves Krintafel (tafenoquine) for the radical cure of P. vivax malaria

R&D, Access & product management

US FDA Advisory Committee endorses the effectiveness and safety of single-dose tafenoquine for the radical cure of P. vivax malaria

R&D, Access & product management

MMV Project of the Year 2017 awarded to Sanofi

Strides Shasun’s rectal artesunate product receives WHO prequalification

Access & product management

MMV deeply saddened by the loss of Prof. Ogobara Doumbo

Australia renews commitment to MMV and R&D for malaria

MMV partner Kelly Chibale in Fortune Greatest Leaders list 2018

MMV’s contributions to malaria commended at MIM conference

Major study confirms tolerability and high efficacy of 4 gold-standard malaria medicines, when used for repeated treatment over a 2 year period

WHO provides first-ever approval for rectal artesunate product for severe malaria

Access & product management

MMV welcomes Philip Welkhoff, new Malaria Program Director, BMGF

MMV and DNDi deliver joint statement at WHO Executive Board

MMV end-of-year review 2017

WHO issues information note on correct use of rectal artesunate for severe malaria

Access & product management

Unitaid awards MMV new supply side grant

Access & product management

PLOS Medicine publishes New Malaria Eradication Road Map

Two new MMV-supported research sites inaugurated in Ethiopia

Two MMV partners receive international award

Global malaria response “off track” in 2016

GSK submits US regulatory application for single-dose tafenoquine for Plasmodium vivax malaria

USAID renews support to MMV with new grant

100 million vials of injectable artesunate distributed since 2010

Access & product management

MMV backs training course for study coordinators

MMV and Transaid partner to tackle severe malaria in Zambia

Access & product management

MMV hosts international drug discovery meeting in Geneva

Three vivax research teams awarded MMV Project of the Year 2016

MMV discovery partners receive ASBMB awards

KAF156 enters phase IIb combination studies

Everything you always wanted to know about malaria and more

Cipla launches quality-assured Rectal Artesunate Suppositories for severe malaria in young children

Access & product management

Pages

1
2
3
4
5
6
7
next ›
last »

Follow us

Facebook
LinkedIn
Twitter
YouTube

Subscribe

Sign up to our monthly newsletter

Previous newsletters

Contact us

Tel: +41 22 555 03 00
- Message us
- Office directions

© MMV 2020

Website by Manta Ray Media

Glossary
Disclaimer
Privacy
Sitemap